Resurgence.

Here is what 2020 has taught us so far about the trade-offs of forfeiting standard cancer treatments to minimize exposure to COVID-19. While things like data-driven hypofractionation just make sense, forgoing other things like cancer screening or systemic therapies probably don’t. | Disis, JAMA 2020